Gareth Macdonald
April 20, 2021
2 Min Read
Image: iStock/Anawat_s
Oxford Biomedica is optimizing its vector production system to boost yields and accelerate production in response to growing demand.
The UK gene and gene therapy firm and contract development and manufacturing organization (CDMO) talked about efforts to improve its vector production platform last week during its Q4 presentation.
The main aim – according to chief scientific officer Kyri Mitrophanous – is to increase viral vector production capacity and remain competitive.
Image: iStock/Anawat_s
“We continue to invest in the lentiviral vector platform in order to maintain our lead in this area and to further industrialize the manufacturing processes.